These studies suggest that a subset of these potential markers, RPTPα pY798 and PKCδ pY313 in particular, represent promising biomarkers of response to dasatinib and may represent sensitive measurable downstream surrogates of Src inhibition and overall response in CRC. This evidence concerns the gene PTPRA and colorectal carcinoma.